Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy/Teva Prohibited From Marketing Generic Quinapril

This article was originally published in The Pink Sheet Daily

Executive Summary

A federal appeals court affirmed a district court decision Nov. 22 that Teva/Ranbaxy's generic quinapril must remain off the market.

You may also be interested in...

Accupril Generics Come Off The Market Following Preliminary Injunction

Teva and Ranbaxy plan to appeal the district court ruling in favor of Pfizer to the federal appeals court. Pfizer said it will seek damages for lost Accupril sales since the December launch of Teva/Ranbaxy’s quinapril.

Teva/Ranbaxy Launch First Generic Of Pfizer’s Accupril

Teva, which relinquished 180-day exclusivity, is marketing quinapril manufactured under Ranbaxy’s ANDA pursuant to a supply and distribution agreement. Teva/Ranbaxy’s product gets a jump on at least five other potential generic competitors; timing of the generic’s launch may have been earlier than expected by Pfizer.

NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination

Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts